Author: Diana Starr

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Cantex Pharmaceuticals announced the publication in the peer-reviewed journal, npj Breast Cancer, reporting results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition. Cantex’s azeliragon is a RAGE inhibitor that is orally administered and taken once daily....

10 August, 2023

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

Cantex Pharmaceuticals, Inc. today announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA. Stephen G. Marcus, M.D. Cantex’s Chief Executive Officer, will present a corporate overview to strategics/big Pharma, VCs, family offices, hedge funds, and government/non-profit grantmakers....

15 June, 2023

CANTEX PHARMACEUTICALS OBTAINS EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM GEORGETOWN UNIVERSITY FOR AZELIRAGON AS A POTENTIAL TREATMENT OF CANCER-RELATED COGNITIVE DECLINE

Cantex Pharmaceuticals announced that it obtained an exclusive worldwide license from Georgetown University for intellectual property related to the potential use of azeliragon to treat, prevent or alleviate cancer-treatment related cognitive decline....

01 June, 2023

Cantex Pharmaceuticals Announces Issuance of a Patent for Azeliragon as a Treatment of Glioblastoma

Cantex Pharmaceuticals announced today that the USPTO has issued U.S. Patent No. 11,648,235, titled “Treatment of Glioblastoma,” with claims to a method of treating glioblastoma with azeliragon. This patent will expire in 2042....

16 May, 2023

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Cantex’s azeliragon is an orally administered inhibitor of the receptor for advanced glycation end products (known as RAGE). Excessive activation of RAGE has been strongly implicated in life-threatening complications of COVID-19 infection, including lung and kidney failure. A protein produced by the immune system, known as “suPAR”, at high levels...

19 April, 2023

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Cantex Pharmaceuticals and Baptist Health Miami Cancer Institute, part of Baptist Health Cancer Care, the largest cancer program in South Florida, announced today that the U.S. Food and Drug Administration (FDA) has issued a “Study May Proceed” letter for the Miami Cancer Institute’s investigator initiated clinical trial to assess the...

06 March, 2023

Cantex Pharmaceuticals Announces Sale of Equity Interest in Chimerix, Inc.

WESTON, FL – September 14, 2021 – Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.   About Cantex Pharmaceuticals Cantex Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on the transformation...

21 September, 2021

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer

  HIGH POINT, N.C. and WESTON, FL– June 22, 2021 – vTv Therapeutics Inc. ("vTv", Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. ("Cantex") today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel antagonist of RAGE (the receptor...

22 June, 2021